Bryn Mawr Capital Management LLC Has $3.59 Million Stock Holdings in Stryker Co. (NYSE:SYK)

Bryn Mawr Capital Management LLC grew its stake in Stryker Co. (NYSE:SYK) by 0.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,970 shares of the medical technology company’s stock after acquiring an additional 39 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Stryker were worth $3,590,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. Shayne & Jacobs LLC acquired a new position in shares of Stryker during the 4th quarter worth about $211,000. Argonautica Private Wealth Management Inc. grew its holdings in Stryker by 3.0% during the fourth quarter. Argonautica Private Wealth Management Inc. now owns 7,805 shares of the medical technology company’s stock worth $2,810,000 after purchasing an additional 225 shares during the period. Lake Street Advisors Group LLC increased its position in Stryker by 4.1% during the fourth quarter. Lake Street Advisors Group LLC now owns 3,175 shares of the medical technology company’s stock worth $1,146,000 after buying an additional 124 shares during the last quarter. Pinnacle West Asset Management Inc. increased its position in Stryker by 7.0% during the fourth quarter. Pinnacle West Asset Management Inc. now owns 765 shares of the medical technology company’s stock worth $275,000 after buying an additional 50 shares during the last quarter. Finally, Longbow Finance SA bought a new stake in Stryker in the fourth quarter valued at approximately $8,890,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on SYK. Stifel Nicolaus boosted their target price on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Wells Fargo & Company raised their target price on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research report on Tuesday. Argus set a $450.00 target price on Stryker in a research report on Monday, February 3rd. Finally, Barclays increased their price objective on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $422.15.

Stryker Stock Up 0.7 %

Shares of NYSE SYK opened at $390.57 on Wednesday. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a market cap of $149.03 billion, a PE ratio of 50.33, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. The company has a 50 day simple moving average of $378.78 and a 200 day simple moving average of $370.22.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the company earned $3.46 earnings per share. On average, research analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is currently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.